San Diego-based Dexcom, a leading diabetes technology company known for its wearable glucose monitors, is expanding its NIL ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Shares of DexCom Inc. DXCM slid 3.59% to $66.11 Monday, on what proved to be an all-around rough trading session for the ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its ...

NEW YORK, April 22, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM ) breached their ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

San Diego-based Dexcom submitted its 15-day G7 CGM to the FDA in October 2024. The company says its 15-day G7 also meets ...

If you're using a Dexcom G7 to monitor your blood sugar in real-time, you can now sync it to your Apple Watch for real-time ...

FDA clears Dexcom G7 15-Day CGM for adults, offering 15.5 days of wear and a MARD of 8.0% for improved diabetes management.

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Shares traded 8.5% higher at $72.55. The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 ...